Ambalal Sarabhai Enterprises Limited (NSE:AMBALALSA)
India · Delayed Price · Currency is INR 32.86
+0.11 (0.34%)
At close: May 22, 2026
NSE:AMBALALSA Revenue
In the fiscal year ending March 31, 2026, Ambalal Sarabhai Enterprises had annual revenue of 2.17B INR with 10.19% growth. Ambalal Sarabhai Enterprises had revenue of 806.59M in the quarter ending March 31, 2026, with 22.28% growth.
Revenue
2.17B
Revenue Growth
+10.19%
P/S Ratio
1.17
Revenue / Employee
3.98M
Employees
104
Market Cap
2.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.17B | 201.11M | 10.19% |
| Mar 31, 2025 | 1.97B | 230.03M | 13.20% |
| Mar 31, 2024 | 1.74B | 32.87M | 1.92% |
| Mar 31, 2023 | 1.71B | -266.02M | -13.46% |
| Mar 31, 2022 | 1.98B | 324.75M | 19.66% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ambalal Sarabhai Enterprises | 2.17B |
| Sat Kartar Life | 2.01B |
| Everest Organics | 1.89B |
| Medicamen Biotech | 1.72B |
| Gennex Laboratories | 1.52B |
| Trident Lifeline | 1.29B |
| Kerala Ayurveda | 1.27B |
| Astonea Labs | 1.17B |
Ambalal Sarabhai Enterprises News
- 2 months ago - EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity - Benzinga